Top 10 Life Science VC (Venture Capital) Funds in Ireland in February 2025

Last updated: Feb 2025 A list of 10 VC (Venture Capital) funds that invest in Life science startups based in Ireland. We rank investors based on the number of investments they made in Life science companies from Ireland. We update this investor list every month.

Top 10 Life Science VC (Venture Capital) Funds in Ireland in February 2025

Investor	Life Science Ireland investments
Enterprise Ireland	6
AIB Seed Capital Fund	5
SOSV	3
European Investment Bank	1
KBI Biopharma	1
The Yield Lab	1
Johnson & Johnson Innovation – JJDC	1
Carbery Group	1
Development Capital	1
Ireland Strategic Investment Fund	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Advise — Advise Freemium is a ground-breaking automated data analytics for CPG solution. Discover how Advise can assist your Revenue Growth Management.
NUA Surgical — NUA Surgical is an award-winning Irish MedTech company developing innovative solutions in obstetrics and gynaecology.
LaNua Medical — At LaNua Medical it is our mission to develop disruptive image-guided technologies providing safe and effective endovascular solutions.

The AIB Seed Capital Fund was established in 2007 to provide venture capital for companies at the seed and early stages of development across a range of sectors throughout the Republic of Ireland. The Fund was established under the Enterprise Ireland Seed and Venture Capital Programme 2007-2012.The Fund has a total of â‚¬30m under managementwith AIB and Enterprise Ireland both committing â‚¬15m. It is managed by experienced managers with extensive expertise in making seed and early stage investments, adding value and facilitating business success.The Fund managers are empowered to make seed investments of up to approximately â‚¬500,000. Furthermore, the Fund has the capacity to make investments in later rounds to support the continued growth of investee companies.The Fund will be managed by Enterprise Equity Venture Capital and the Dublin Business Innovation Centre. This unique partnership brings together extensive regional and investment expertise.Enterprise Equity will evaluate and manage all investments outside the city and county of Dublin, as well as investments that require in excess of â‚¬250,000 from the fund within the city and county of Dublin.Dublin Business Innovation Centre (DBIC) will evaluate and manage all investments within the city and county of Dublin when the initial investment amount required from the Fund does not exceed â‚¬250,000.

Investment focus

Software, Health Care, Medical
Seed, Funding Round, Series A
Ireland, United States, Jersey

Portfolio highlights

NewsWhip — The only real-time media monitoring platform that predicts the stories and topics that will matter in the hours ahead.
Offr — Offr is the new way to buy and sell property, quickly and transparently.
Metabolomic Diagnostics — Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

The European Investment Bank (EIB) offers lending, borrowing, and treasury services primarily within the European Union. It provides project loans for public and private sectors, loans to banks and intermediaries, structured finance products, guarantees, and securitization instruments for debts. Additionally, EIB offers equity and fund investmentproducts, including infrastructure and environmental funds, as well as venture capital funds. EIB also supports microfinance and risk-sharing finance for research and innovation and provides technical expertise for sustainable energy projects. Its services include infrastructure advisory, urban development support, guarantees for transport infrastructure, and funding for public-private partnerships and small- to medium-sized enterprises. The bank serves various sectors, including transportation, energy, health, education, and agriculture.

Investment focus

Biotechnology, Health Care, Energy
Debt Financing, Post-IPO Debt, Funding Round
Germany, France, The Netherlands

Portfolio highlights

Amadix — Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide.The most advancedproduct developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients).Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.
Greenlight Biosciences — Next Generation Crop Protection
Azienda Comprensoriale Acquedottistica — ACA Spa is an integrated water service company.

KBI Biopharma Inc. is a global contract development and manufacturing organization (CDMO / CMO) offering Cell Line Development, Process Analytical & Formulation Development, Clinical & Commercial Manufacturing, and more.

Investment focus

Biotechnology, Life Science, Medical
Seed, Series A, Series D
United States, Ireland

Portfolio highlights

Absci — A better, faster path to new medicines. We translate ideas into drugs with an AI-powered approach to biologic drug discovery and cell line development.
GlycoSeLect — GlycoSeLect Ltd specialises in the development and production of Recombinant Prokaryotic Lectins (RPLs).
Comera Life Sciences — ReForm Biologics is an engineering superior biotherapeutic formulation for fragile patients. Its proprietary technology provides patented, FDA-friendly excipients for a wide range of therapeutic biologics. Using its platforms, drug companies can make life-saving medicines easier to administer, less immunogenic, more stable, and more efficient toproduce. It was founded in 2014 and is based in Woburn, Massachusetts.

The Yield Lab invests in AgriFood Tech companies with technologies focused on crops, animal health, digital agriculture, logistics, and food ingredients. Initial investments range from $100,000 – $1.5M.

Investment focus

Agriculture, Biotechnology, AgTech
Seed, Series A, Convertible Note
United States, Argentina, Brazil

Portfolio highlights

Spotta — Spotta's smart pest systems help pest control monitor and identify pests. Solutions for hospitality, care homes, agriculture, farming and forestry.
Sundew — Targeting water-borne pests and diseases
Kaffe Bueno — Kaffe Bueno upcycles coffee waste into active and functional ingredients for cosmetics, nutraceuticals and functional foods.

JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Israel, France

Portfolio highlights

Citryll — Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
Cala Health — Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is an essential tremor, adisease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.
G.I. Windows — G.I. Windows is a clinical-stage company developing the first fundamental breakthrough in surgical anastomotic technology. This technology will allow less invasive surgery and offer the capability of developing more procedures new to the world. The company is creating a new category in healthcare designed to create less invasive surgery and reducehealthcare costs.G.I. Windows is committed to innovation that helps improve the way diagnostic and interventional procedures impact the essential balance between both patients and the healthcare system. It was founded in 2012 and is headquartered in West Bridgewater, Massachusetts, United States.

Pioneering research and expertise in action. Through innovati drive new product innovation that creates value for our.

Investment focus

Life Science, Biotechnology, Marine Technology
Seed
Ireland

Portfolio highlights

Pure Ocean Algae — Pure Ocean Algae is a biotechnology company that integrates value chains from macro-algae and other marine resources. The company has over the winter of 2019/20 deployed its first trial lines of Palmaria palmata to sea, with initial results being extremely positive. It has also taken primary research in tank-based vegetative production andsucceeded in developing a pilot commercial plant that can produce commercial volumes of Palmaria palmata, at levels approaching 100% per week.

At Development Capital, they are aware of the significant growth opportunities available to mid-sized companies and understand the management teams’ unique requirement for not only finance, but also for a funding partner who will bring experience, expertise and international reach to assist secure and maximise the business growth opportunity.Development Capital provides investee companies with a unique and unprecedented partnership approach which will maximise the growth opportunity in the most prompt and efficient manner. In addition to their experienced Investment Directors, their partners include:High profile and experienced Industry Experts who will provide direction and support to investee companies; andMajor Irish Corporates who have committed not only funding but also their international experience.

Investment focus

Manufacturing, Telecommunications, VoIP
Funding Round, Seed, Private Equity
Ireland, United States, United Kingdom

Portfolio highlights

IP Telecom — Ireland's most competitive SME & Enterprise VoIP provider. We are Ireland's leading VoIP Phone Systems Provider. Connect your business to the technology of today.
Nomadic Dairy — Nomadic Dairy is a growing, premium branded yogurt manufacturer. The company supplies multiple products across the UK and Republic of Ireland.
Spotlight Oral Care — Spotlight Oral Care aims to create the best oral health products, to educate and promote oral care, empowering people to engage with true customised preventative oral care.

The Ireland Strategic Investment Fund, managed and controlled by the National Treasury Management Agency (NTMA), is an €8.5 billion sovereign development fund with a unique mandate. We have a statutory mandate to invest on a commercial basis in a manner designed to support economic activity and employment in Ireland. With €8.5 billion availableto deploy, the Fund differs from other pools of capital in a number of key respects. It has a long investment time horizon and therefore can act as a permanent or patient source of long-term capital. It has flexibility up and down the capital structure and can therefore meet changing capital needs and gaps in the marketplace.The Fund will seek to invest in transactions where it can make a difference, where its characteristics can enable commercial investment transactions with positive economic impact and can make it an attractive “investor of choice” for company and project sponsors and advisors.We are a strategic investor with strong connections in both the public and private sectors. We are uniquely positioned to make connections and drive innovation across multiple industry players developing and delivering innovative opportunities that might otherwise go unrealised.